Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance-Reference-Cited by-同舟云学术

Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance

Published:2012-08 Issue:4 Volume:15 Page:183-210
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Gonen Nitzan,Assaraf Yehuda G.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference417 articles.

1. Regulation of human dihydrofolate reductase activity and expression;Abali;Vitamins & Hormones,2008

2. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426;Adjei;Journal of Clinical Oncology,2010

3. Two different species of dihydrofolate reductase in mammalian cells differentially resistant to amethopterin and methasquin;Albrecht;Cancer Research,1972

4. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates;Allegra;Journal of Biological Chemistry,1985

5. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate;Allegra;Journal of Biological Chemistry,1987

Cited by 370 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Possible hemoglobin enhancing effect of phytol in methotrexate-induced folate deficient Swiss albino mice: In vivo and in silico studies;Pharmaceutical Science Advances;2024-12

2. Direct radiolabeling of Folate with Tc-99m using QbD approach: A step closer to folate based diagnostic agent;Applied Radiation and Isotopes;2024-11

3. Folylpolyglutamate synthetase inactivation in relapsed ALL induces a druggable folate metabolic vulnerability;Drug Resistance Updates;2024-11

4. Synergetic Effect of β-Cyclodextrin and Its Simple Carbohydrate Substituents on Complexation of Folic Acid and Its Structural Analog Methotrexate;Pharmaceutics;2024-09-03

5. Lipidomics and metabolomics as potential biomarkers for breast cancer progression;npj Metabolic Health and Disease;2024-09-02